1. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S32-7. doi: 10.1086/383050. PMID: 15250018.
2. Rapoport BL, Aapro M, Paesmans M, van Eeden R, Smit T, Krendyukov A, et al. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult
patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. BMC Cancer. 2018;18:917. doi:
10.1186/s12885-018-4838-z.
3. Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young, John R. Wingard, Clinical Practice
Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases, Volume 52, Issue
4, 15 February 2011, Pages e56–e93, https://doi.org/10.1093/cid/cir073.
4. Link H. Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF). Support Care Cancer. 2022 Sep;30(9):7067-7077. doi: 10.1007/s00520-022-07103-5. PMID:
35739328; PMCID: PMC9225876.
5. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-¬ induced neutropenia in children with cancer or after hemopo-
ietic stem cell transplantation. Clin Infect Dis. 2007;45:1296–1304.
6. Velasco E, Byington R, Martins CA, et al. Comparative study of clinical characteristics of neutropenic and non-¬ neutropenic adult cancer patients with bloodstream infections. Eur J Clin
Microbiol Infect Dis. 2006;25:1–7.
7. Schelenz S, Nwaka D, Hunter PR. Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial
resistance. J Antimicrob Chemother. 2013;68(6):1431–1438.
8. Carlisle PS, Gucalp R, Wiernik PH. Nosocomial infections in neutropenic cancer patients. Infect Control Hosp Epidemiol. 1993;14:320–324.
9. Zakhour R, Chaftari AM, Raad II. Catheter-¬ related infections in patients with haematological malignancies: novel preventive and therapeutic strategies. Lancet InfectDis. 2016;16:e241–
e250.
10. Kulkarni S, Wu O, Kasthuri R, et al. Centrally inserted external catheters and totally implantable ports for the delivery of chemotherapy: a systematic review and meta-¬ analysis of device-¬
related complications. Cardiovasc Intervent Radiol. 2014;37:990–1008.
11. Viscoli C.,Castagnola E. Prophylaxis and empirical therapy for infection in canser patients.In:Mandell GL.,BennetJE,Dolin R(eds).Principles and Practice of Infectious Disease.
12. Özlem Güzel Tunçcan. Hematoloji ve Kök Hücre Nakil Ünitelerinde Takip Edilen Hastaların Kan Kültürlerinden İzole Edilen Mikroorganizmaların Sıklığı ve Antibiyotik Direnç Sonuçları,5
yıl(2010-2014). Febril nötropeni simpozyumu-P103.
13. Castagnola E, Bagnasco F, Mesini A, et al. Antibiotic resistant bloodstream infections in pediatric patients receiving chemotherapy or hematopoietic stem cell transplant: factors associated
with development of resistance, intensive care admission and mortality. Antibiotics (Basel). 2021;10(3).
14. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S25-31.
doi: 10.1086/383048. PMID: 15250017.
15. Sallah, Ya Haddy et al. The Lancet Oncology, Volume 26, Issue 5, e242 – e252 https://doi.org/10.1016/S1470-2045(25)00079-8.
16. Baccelli F, Aguilar-Guisado M, Vidal CG, Mikulska M, Vanbiervliet Y, Blijlevens N, Muñoz P, Neofytos D, Cordonnier C, Calandra T, Averbuch D, Akova M. Epidemiology of resistant bac-
terial infections in patients with hematological malignancies or undergoing hematopoietic cell transplantation in Europe: A systematic review by the European Conference on Infections in
Leukemia (ECIL). J Infect. 2025 Sep;91(3):106571. doi: 10.1016/j.jinf.2025.106571. Epub 2025 Aug 12. PMID: 40812455.
17. Cornely OA, Gachot B, Akan H, et al. Epidemiology and mortality of fungaemia in cancer patients—a clinical cohort of the Infectious Diseases Group (IDG) of the European Organization
for Research and Treatment of Cancer (EORTC 65031) [oral presentation O109]. In:Program and Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases.
London, UK: European Society of Clinical Microbiology and Infectious Diseases; 2012.
18. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum
inhibitory concentrations. Clin Infect Dis. 2013;56:1724–1732.
19. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-¬ 2004 study. Haematologica. 2006;9:1068–1075.
20. Afsharian P, Möllgård L, Hassan Z, et al. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-¬ Hodgkin lymphoma. Eur J Haematol. 2005;75:206–211.
21. Teh BW, Yeoh DK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Intern Med J.
2021;51(Suppl 7):67–88.
22. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
23. Stemler J, de Jonge N, Skoetz N, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus
recommendation from the European Hematology Association. Lancet Haematol. 2022;9(5):e361e373.
24. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
J Antimicrob Chemother. 2016;71:2397–2404.
25. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio
JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection
after allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 9;116(24):5111-8. doi: 10.1182/blood-2010-02-268151. Epub 2010 Sep 8. PMID: 20826719; PMCID: PMC3012532.
26. NCCN guidelines version. 1.2025.
27. Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromi-
sed participants, and infants: varicella outcomes and safety results from a large, open-¬ label, expanded-¬ access program. PLoS One. 2019;14(7):e0217749.
28. Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P, McDonald GB, Hirsch H; Center for International Blood and Marrow Transplant Research; National Marrow Donor Prog-
ram; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of
America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention. Viral disease
prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Oct;44(8):471-82. doi: 10.1038/bmt.2009.258. PMID: 19861981; PMCID: PMC7091730.
29. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG,
Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75.
doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10. PMID: 23234725.
30. Ba Y, Shi Y, Jiang W, Feng J, Cheng Y, Xiao L, Zhang Q, Qiu W, Xu B, Xu R, Shen B, Luo Z, Xie X, Chang J, Wang M, Li Y, Shuang Y, Niu Z, Liu B, Zhang J, Zhang L, Yao H, Xie C, Huang H,
Liao W, Chen G, Zhang X, An H, Deng Y, Gong P, Xiong J, Yao Q, An X, Chen C, Shi Y, Wang J, Wang X, Wang Z, Xing P, Yang S, Zhou C. Current management of chemotherapy-induced
neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China An-
ti-Cancer Association. Cancer Biol Med. 2020 Nov 15;17(4):896-909. doi: 10.20892/j.issn.2095-3941.2020.0069. Epub 2020 Dec 15. PMID: 33299642; PMCID: PMC7721096.
31. Alenzi EO, Kelley GA. The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: a systematic review with meta-a-
nalysis. J Diabetes Complications. 2017;31:267–72. doi: 10.1016/j.jdiacomp.2016.09.006.
32. Alison Freifeld, M.D., Donna Marchigiani, R.N., Thomas Walsh, M.D., StephenChanock, M.D., Linda Lewis, M.D., John Hiemenz, M.D., Sharon Hiemenz, R.N., Jeanne E.Hicks, M.D., Vee
Gill, Ph.D., Seth M. Steinberg, Ph.D., and Philip A. Pizzo, M.D. Published July 29, 1999 N Engl J Med 1999;341:305-311 DOI: 10.1056/NEJM199907293410501.
33. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer
risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000 Aug;18(16):3038-51. doi: 10.1200/JCO.2000.18.16.3038. PMID:
10944139.
34. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of
America. Clin Infect Dis. 2011;52:e56–e93.
35. Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-¬ risk neutropenic patients with cancer: a double-¬ blind, randomized, multicenter trial comparing single daily moxif-
loxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy— EORTC Infectious Diseases Group Trial XV. J Clin Oncol. 2013;31:1149–1156.
36. Günalp M, Koyunoğlu M, Gürler S, Koca A, Yeşilkaya I, Öner E, Akkaş M, Metin Aksu N, Demirkan A, Polat O, Elhan AH. Independent factors for prediction of poor outcomes in patients
with febrile neutropenia. Med Sci Monit. 2014 Oct 5;20:1826-32. doi: 10.12659/MSM.892269. PMID: 25282155; PMCID: PMC4199395.
37. Averbuch D, Vanbiervliet Y, Baccelli F, Mikulska M, Neofytos D, Garcia-Vidal C, Aguilar-Guisado M, Blijlevens N, Munoz P, Cordonnier C, Akova M, Calandra T. Empirical and targeted
antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference
on Infections in Leukaemia. Lancet Infect Dis. 2025 Nov 25:S1473-3099(25)00619-X. doi: 10.1016/S1473-3099(25)00619-X. Epub ahead of print. PMID: 41314221.
38. ECIL 4, Haematologica 2013;98(12): 1826-35.
39. CINAR, G., ÖCAL, D., SEVAL, G. C., KALKAN, İ. A., GÜLTEN, E., SARICAOĞLU, E. M., GÜRIZ, H., BOZDAG, S. C., TOPRAK, S. K., YUKSEL, M. K., AZAP, A. (2022). Hematolojik
Febril Nötropeni Ataklarında Kan Kültürlerinden İzole Edilen Gram-negatif Bakterilerin Dağılımı ve Antimikrobiyal Duyarlılıklarının Değerlendirilmesi. Ankara Üniversitesi Tıp Fakültesi
Mecmuası , 75(3), 373 – 378. doi.org/10.4274/atfm.galenos.2022.58070DOI: 10.4274/atfm.galenos.2022.58070.
40. Zimmer AJ, Stohs E, Meza J, Arnold C, Baddley JW, Chandrasekar P, El Boghdadly Z, Gomez CA, Maziarz EK, Montoya JG, Pergam S, Rolston KV, Satlin MJ, Satyanarayana G, Shoham S,
Strasfeld L, Taplitz R, Walsh TJ, Young JH, Zhang Y, Freifeld AG. Bloodstream Infections in Hematologic Malignancy Patients With Fever and Neutropenia: Are Empirical Antibiotic Therapies
in the United States Still Effective? Open Forum Infect Dis. 2022 May 18;9(7):ofac240. doi: 10.1093/ofid/ofac240. PMID: 35854988; PMCID: PMC9277632.
41. Marchesi F, Toma L, Di Domenico EG, et al. Ceftolozane-tazobactam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae:
preliminary results from a prospective cohort study. Mediterr J Hematol Infect Dis. 2020;12(1):e2020065.
42. Chaftari AM, Hachem R, Malek AE, et al. A prospective randomized study comparing ceftolozane/tazobactam to standard of care in the management of neutropenia and fever in patients with
hematological malignancies. Open Forum Infect Dis. 2022;9(6):ofac079.
43. Aguilar-¬ Guisado M, Espigado I, Martín-¬ Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies an febrile neutropenia (How Long
study): an open-¬ label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4:e573–e583.
44. de Jonge NA, Sikkens JJ, Zweegman S, Beeker A, Ypma P, Herbers AH, Vasmel W, de Kreuk A, Coenen JLLM, Lissenberg-Witte B, Kramer MHH, van Agtmael MA, Janssen JJWM. Short
versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. Lancet
Haematol. 2022 Aug;9(8):e563-e572. doi: 10.1016/S2352-3026(22)00145-4. Epub 2022 Jun 9. Erratum in: Lancet Haematol. 2022 Sep;9(9):e641. doi: 10.1016/S2352-3026(22)00261-7. PMID:
35691326.
45. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a ran- domized, controlled trial. Clin Infect Dis 2009;
48:1042–51.
46. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;
100:345–51.